Inflammation and progressive nephropathy in type 1 diabetes in the diabetes control and complications trial

Diabetes Care

Volumn 31, Issue 12, 2008, Pages 2338-2343

  Lin, Julie ^a   Glynn, Robert J ^a,b   Rifai, Nader ^c   Manson, Joann E ^a,b   Ridker, Paul M ^a   Nathan, David M ^d   Schaumberg, Debra A ^a,b,e  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c BOSTON CHILDREN S HOSPITAL   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e SCHEPENS EYE RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; SOLUBLE INTERCELLULAR ADHESION MOLECULE 1; SOLUBLE TUMOR NECROSIS FACTOR ALPHA RECEPTOR 1; SOLUBLE VASCULAR CELL ADHESION MOLECULE 1; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ADOLESCENT; ADULT; ALBUMINURIA; ALLOPATHY; ARTICLE; BLOOD SAMPLING; CARDIOVASCULAR RISK; CLINICAL TRIAL; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES CONTROL; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; DISEASE COURSE; DISEASE DURATION; ENDOTHELIAL DYSFUNCTION; FEMALE; HUMAN; INCIDENCE; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; INTENSIVE CARE; KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; MORBIDITY; MORTALITY; MULTICENTER STUDY; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; URINALYSIS; URINARY EXCRETION; VASCULAR ENDOTHELIUM;

ADOLESCENT; ADULT; ALBUMINURIA; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; DIABETES MELLITUS, TYPE 1; DIABETIC NEPHROPATHIES; FEMALE; HUMANS; IMMUNOGLOBULIN G; INFLAMMATION; INTERCELLULAR ADHESION MOLECULE-1; MALE; PROPORTIONAL HAZARDS MODELS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, TUMOR NECROSIS FACTOR; VASCULAR CELL ADHESION MOLECULE-1; YOUNG ADULT;

EID: 64349120378     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc08-0277     Document Type: Article

References (25)

1. Ndumele CE, Pradhan AD, Ridker PM: Interrelationships between inflammation, C-reactive protein, and insulin resistance. J Cardiometab Syndr 1:190-196, 2006
2. Ichinose K, Kawasaki E, Eguchi K: Recent advancement of understanding pathogenesis of type 1 diabetes and potential relevance to diabetic nephropathy. Am J Nephrol 27:554-564, 2007
3. Williams MD, Nadler JL: Inflammatory mechanisms of diabetic complications. Curr Diab Rep 7:242-248, 2007
4. Furuta T, Saito T, Ootaka T, Soma J, Obara K, Abe K, Yoshinaga K: The role of macrophages in diabetic glomerulo- sclerosis. Am J Kidney Dis 21:480-485, 1993
5. Saraheimo M, Teppo AM, Forsblom C, Fagerudd J, Groop PH: Diabetic nephropathy is associated with low-grade inflammation in type 1 diabetic patients. Diabetologia 46:1402-1407, 2003
6. Zoppini G, Faccini G, Muggeo M, Zenari L, Falezza G, Targher G: Elevated plasma levels of soluble receptors of TNF-α and their association with smoking and mi- crovascular complications in young adults with type 1 diabetes. JClin Endocri- nol Metab 86:3805-3808, 2001
7. Clausen P, Jacobsen P, Rossing K, Jensen JS, Parving HH, Feldt-Rasmussen B: Plasma concentrations of VCAM-1 and ICAM-1 are elevated in patients with type 1 diabetes mellitus with microalbumin- uria and overt nephropathy. Diabet Med 17:644-649, 2000
8. Hillege HL, Fidler V, Diercks GF, van Gilst WH, de Zeeuw D, van Veldhuisen DJ, Gans RO, Janssen WM, Grobbee DE, de Jong PE: Urinary albumin excretion predicts cardiovascular and noncardio- vascular mortality in general population. Circulation 106:1777-1782, 2002
9. Solomon SD, Lin J, Solomon CG, Jablon- ski KA, Rice MM, Steffes M, Domanski M, Hsia J, Gersh BJ, Arnold JM, Rouleau J, Braunwald E, Pfeffer MA: Influence of al- buminuria on cardiovascular risk in patients with stable coronary artery disease. Circulation 116:2687-2693, 2007
10. Prince CT, Becker DJ, Costacou T, Miller RG, Orchard TJ: Changes in glycaemic control and risk of coronary artery disease in type 1 diabetes mellitus: findings from the Pittsburgh Epidemiology of Diabetes Complications Study (EDC). Diabetologia 50:2280-2288, 2007
11. Mohanty P, Hamouda W, Garg R, Aljada A, Ghanim H, Dandona P: Glucose challenge stimulates reactive oxygen species (ROS) generation by leucocytes. JClin En- docrinol Metab 85:2970-2973, 2000
12. Pigott R, Dillon LP, Hemingway IH, Gearing AJ: Soluble forms of E-selectin, ICAM-1 and VCAM-1 are present in the supernatants of cytokine activated cultured endothelial cells. Biochem Biophys Res Commun 187:584-589, 1992
13. Aljada A, Friedman J, Ghanim H, Mo- hanty P, Hofmeyer D, Chaudhuri A, Dan- dona P: Glucose ingestion induces an ncrease in intranuclear nuclear factor κB, a fall in cellular inhibitor kB, and an increase in tumor necrosis factor α messenger RNA by mononuclear cells in healthy human subjects. Metabolism 55:11771185, 2006
14. Seckin D, Ilhan N, Ertugrul S: Glycaemic control, markers of endothelial cell activation and oxidative stress in children with type 1 diabetes mellitus. Diabetes Res Clin Pract 73:191-197, 2006
15. Aljada A, Dandona P: Effect of insulin on human aortic endothelial nitric oxide syn- thase. Metabolism 49:147-150, 2000
16. Dandona P, Aljada A, Mohanty P, Ghanim H, Hamouda W, Assian E, Ahmad S: Insulin inhibits intranuclear nuclear factor κB and stimulates IκB in mononuclear cells in obese subjects: evidence for an anti-inflammatory effect? J Clin Endocrinol Metab 86:3257-3265, 2001
17. Schaumberg DA, Glynn RJ, Jenkins AJ, Lyons TJ, Rifai N, Manson JE, Ridker PM, Nathan DM: Effect of intensive glycemic control on levels of markers of inflammation in type 1 diabetes mellitus in the diabetes control and complications trial. Circulation 111:2446-2453, 2005
18. Tesfamariam B, DeFelice AF: Endothelial injury in the initiation and progression of vascular disorders. Vascul Pharmacol 46: 229-237, 2007
19. Iiyama K, Hajra L, Iiyama M, Li H, DiChi- ara M, Medoff BD, Cybulsky MI: Patterns of vascular cell adhesion molecule-1 and intercellular adhesion molecule-1 expression in rabbit and mouse atherosclerotic lesions and at sites predisposed to lesion formation. Circ Res 85:199-207, 1999
20. Cybulsky MI, Iiyama K, Li H, Zhu S, Chen M, Iiyama M, Davis V, Gutierrez-Ramos JC, Connelly PW, Milstone DS: A major role for VCAM-1, but not ICAM-1, in early atherosclerosis. J Clin Invest 107: 1255-1262, 2001
21. Okada S, Shikata K, Matsuda M, Ogawa D, Usui H, Kido Y, Nagase R, Wada J, Shikata Y, Makino H: Intercellular adhesion molecule-1-deficient mice are resistant against renal injury after induction of diabetes. Diabetes 52:2586-2593, 2003
22. Boyle JJ: Macrophage activation in atherosclerosis: pathogenesis and pharmacology of plaque rupture. Curr Vasc Pharmacol 3:63-68, 2005
23. Albert MA, Glynn RJ, Buring JE, Ridker PM: Relation between soluble intercellular adhesion molecule-1, homocysteine, and fibrinogen levels and race/ethnicity in women without cardiovascular disease. Am J Cardiol 99:1246-1251, 2007
24. Pradhan AD, Rifai N, Ridker PM: Soluble intercellular adhesion molecule-1, soluble vascular adhesion molecule-1, and the development of symptomatic peripheral arterial disease in men. Circulation 106: 820 -825, 2002
25. Soehnlein O, Schmeisser A, Cicha I, Reiss C, Ulbrich H, Lindbom L, Daniel WG, arlichs CD: ACE inhibition lowers an- giotensin-II-induced monocyte adhesion to HUVEC by reduction of p65 transloca- tion and AT 1 expression. J Vasc Res 42: 399-407, 2005